Jul. 3 at 12:33 AM
$NRSN The NeuroDex PR is the most important scientific document published this week, more important than the NeuroSense PR itself because it provides the validation foundation that gives the NeuroSense finding its full scientific context. Published the day after Taylor's critique went public, it answers his concerns with specific data, specific p-values, and a peer-reviewed publication reference. Whether this was deliberately timed as a response to Taylor or was independently planned and happened to coincide is less important than what it contains. Taylor's critique has now been met with more and better public evidence than existed before he raised it. The scientific record around NDE-TDP-43 as a biomarker is measurably stronger now than it was when he posted his first comment. That's a great outcome for the science, for NeuroSense, and ironically for Taylor's goal of ensuring the field has rigorous biomarker standards before drawing clinical conclusions. https://www.send2press.com/wire/neurodex-exosort-platform-demonstrates-treatment-responsive-blood-based-measurement-of-neuronal-tdp-43-in-people-living-with-als/
